Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
368 articles
A 38-year Finnish cohort study finds higher lifelong physical activity protects information processing and working memory into midlife.
A completed pilot trial tested humanoid robots and AI predictive models to manage dementia care at home, personalizing treatment pathways.
New iPSC and cerebral organoid research shows HSV-1 directly activates neurodegeneration and senescence pathways, supporting the viral hypothesis of Alzheimer's disease.
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
A phase 2 RCT finds ABvac40, a vaccine targeting vascular amyloid-β40, is safe and immunogenic in early Alzheimer's patients with no ARIA-E.
β-endorphin released during exercise wraps around toxic Aβ aggregates, forming a 'corona' that shields brain cells from Alzheimer's damage.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
MIT researchers discovered that 30% of adult brain synapses are dormant but ready to activate, reshaping how we understand lifelong learning.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
A liver enzyme released during exercise may rejuvenate brain blood vessels and protect against cognitive decline and Alzheimer's pathology.
A large UK Biobank study finds sleep duration, napping, and sleeplessness independently predict white matter damage tied to dementia risk.
